METTL3 enhances the metastatic potential of CRC cells by promoting m6A modification on pri-miR-1246 to upregulate the level of mature miR-1246, thereby affecting the function of its target gene SPRED2 and the activity of the MAPK pathway[133, 144]. Here, METTL3 is linked to colorectal carcinoma.